Vagonixen™  Duska is identifying, with the potential assistance of third parties, lead compounds that could be developed to serve as drugs for the treatment of chronic obstructive pulmonary disease (COPD), and chronic cough. 

COPD, a chronic disease without a known cure, is the fourth leading cause of death in the U.S; approximately 16 million patients in the US alone are afflicted with this incurable disease.  Bronchodilation is one of the hallmarks of current therapy for COPD.  ATP is known to cause bronchoconstriction and cough in normal subjects, and more so in patients with obstructive airway diseases.  Duska’s proprietary technology is comprised of the selective blockade of specific P2R in the lungs that mediate the bronchoconstrictive cough inducing actions of ATP.

Legend: ATP activates P2X2/3 receptors on vagal sensory nerve terminals in the lungs and thereby induces bronchoconstriction, cough and neurogenic inflammation

 

 

Copyright © 2008 Duska Therapeutics, Inc. 1999-2008 All rights reserved.

 

Duska Therapeutics

info@duskatherapeutics.com

Promising New Medicines